Navigation Links
Avillion LLP Receives Initial Funding From Abingworth and Clarus
Date:1/28/2013

LONDON, January 28, 2013 /PRNewswire/ --

Avillion LLP, which focuses on clinical co-development of therapeutics, today announced that it has received initial funding from Abingworth LLP and Clarus Ventures.

Avillion, based in London, UK, is partnering with pharmaceutical and biotechnology companies to co-developand finance latestage therapeutics. The company will use its clinical development and regulatory expertise to obtain global approvalsfor a broad range of drugs and biologics.

Lewis Cameron , theCEO of Avillion, commented: "Avillion offers pharma and biotech companies a compelling option to partner late stage drug approval projects globally. We have an experienced team focused on global drug development and approval, with the capability to optimise CRO management."

The management team is led by Lewis Cameron (CEO), who has held senior executive positions in CRO companies,including Chiltern International, Clearstone and LabCorp. Dr Allison Jeynes-Ellis (CMO) has over 20 years experience running clinical trials for pharmaceutical companies,including Wyeth and BMS, and has been extensively involved in health technology appraisals across various countries. Graham Higson (VP, Regulatory) has three decades of regulatory experience, including 5 years as the global head of regulatory affairs at AstraZeneca. John Bradshaw (CFO) provides financial services to life sciences companies and has extensive experience in dealing with complex accounting and finance issues relevant to the pharmaceutical industry.

Genghis Lloyd-Harris , a partner at Abingworth, said: "We founded Avillion and incubated the company in our London office. The Avillion team has exceptionally broad and deep experience in CRO management, drug development and regulatory approval. Avillion provides an excellent choice for co-developing phase III drugs and biologics in the US and Europe."

Notes for Editors

About Abingworth

Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sector. The company invests at all stages of development including early and late-stage venture financing, growth equity and public companies.

Founded in 1973, Abingworth has a lengthy track record of backing market leading companies. Abingworth has a specialist team of 19 professionals with a broad range of skill sets and access to an extensive network of industry contacts. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.

About Clarus

Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment and operating professionals. The investment team has extensive and broad backgrounds in research and development, commercialization, business development and operations management, which enabled Clarus to establish a long history of success in creating value across multiple disciplines within the healthcare-investing universe. The deep domain expertise of the Clarus team allows us to employ a hands-on philosophy of providing value enhanced leadership and guidance in working with our management teams in both the biopharmaceutical and medical device arenas. Clarus is presently managing $1.2 billion. The firm invests globally out of its offices in Cambridge, MA and South San Francisco, CA.

Contacts
For Avillion
Lewis Cameron
CEO
Tel: +44(0)207470-2458
lewis@avillionllp.com
http://www.avillionllp.com

For Abingworth
Genghis Lloyd-Harris
Partner
Tel: +44(0)20-7534-1500
lloyd-harris@abingworth.com
http://www.abingworth.com

For Clarus
Kurt Wheeler
Managing Director
Tel: +1-(650)-238-5055
kwheeler@clarusventures.com
http://www.clarusventures.com



'/>"/>
SOURCE Avillion LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. St. Mark’s School Receives $4.8 Million Gift from Tech Pioneer Graduate
2. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
3. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
4. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
5. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
6. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
7. Ceres Receives $3.5 million from USAID for Trait Stacks
8. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
9. Hertz Fellow, Grant I. Gillary, Receives Hertz Foundation-George Lerman Fellowship
10. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
11. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Benchworks announced ... chapter of the Healthcare Businesswomen’s Association (HBA). Nominated by chapter president ... board meets in person once each quarter and holds monthly conference calls. In ...
(Date:5/24/2017)... WASHINGTON, DC, USA (PRWEB) , ... May 23, 2017 , ... ... the economy as well as an enabler of life-saving medical and other vital technologies ... and photonics . They joined others in the scientific community today in responding to ...
(Date:5/23/2017)... Toronto, Canada (PRWEB) , ... May 23, 2017 ... ... of Firmex FileSend, a cloud-based file transfer solution that makes it easy for ... firewall without having to worry about cumbersome FTP software or email file size ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, ... 20th anniversary, marking the occasion with a strong presence at Bio-IT World Conference ... and further extends an invitation to all attendees to view posters on ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):